|MDACC Study No:||2014-0152 (clinicaltrials.gov NCT No: NCT02071927)|
|Title:||A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Relapsed and/or Treatment-Refractory Leukemia and IDH-Mutated Myelodysplastic Syndrome|
|Principal Investigator:||Marina Konopleva|
|Study Description:||The goal of Part I of this clinical research study is to find the highest |
tolerable dose of CB-839 that can be given to patients with relapsed or
refractory AML or ALL.
The goal of Part II of this study is to learn if the dose found in Part 1 of
the study can help to control the disease.
The safety of the study drug will be studied in both parts of this study.